HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

People In Brief

This article was originally published in The Rose Sheet

Executive Summary

Lauder loses one, adds another: Group President Philip Shearer has resigned from Estee Lauder to pursue other opportunities, firm says. Shearer's direct reports now will report to CEO William Lauder until incoming President and Chief Operating Officer Fabrizio Freda arrives in March. In a recent release, CEO Lauder states: "Philip has done a wonderful job over the past six years, initially leading our international business and more recently heading up the Clinique, Origins, Aveda, Bumble and Bumble, and Ojon brands, as well as our online business." Meanwhile, Daniel Rachmanis has been appointed to the newly created position of senior VP-International Business Development, reporting to International President Cedric Prouvé on various international projects and to BeautyBank President Jane Hudis on the international launch of firm's BeautyBank brands, according to Lauder. Rachmanis comes to Lauder from Chemaid Laboratories where as CEO he "restructured Sales & Marketing and Research & Development capabilities to make the company a key player in the premium skin/body/hair-care sector," Lauder says. Prior to his time at Chemaid, Rachmanis served as president, fine fragrances, Americas, at Firmenich. "Daniel was a highly respected partner while on the supplier side and joins us with extensive prior knowledge and understanding of our organization," Prouvé says

Latest Headlines
See All
UsernamePublicRestriction

Register

RS015141

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel